Thursday Jul 3
GSK and Genmab Receive EU Authorization for Arzerra (ofatumumab) as...
Arzerra approved for use in EU as first-line treatment for CLL in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy Approval based on Phase III data from study with ofatumumab + chlorambucil & Phase II data from study with ofatumumab and bendamustine GlaxoSmithKline plc and Genmab A/S announced ... (more)
Roche Medicine Gazyvaro Granted Approval For The Therapy Of Patients...
Roche Medicine Gazyvaro Granted Approval For The Therapy Of Patients With Previously Untreated Chronic Lymphocytic Leukemia And Co-Existing Medical Conditions In Switzerland In a head-to-head comparison with standard therapy with MabThera, Gazyvaro in combination with chemotherapy reduces the risk of disease progression or death in CLL patients by ... (more)